AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

AVROBIO, Inc. to Present at the Cowen and Company 39th Annual Health Care Conference

March 5, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 5, 2019--AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that the Company will present at the Cowen and Company 39 th Annual Health Care Conference on Wednesday, March 13, 2019, at 8:40 a.m. ET at the Marriott Copley Place in Boston.

Geoff MacKay, AVROBIO’s President and Chief Executive Officer, will provide an overview of the Company and a business update. A live webcast of the presentation will also be available under “Events and Presentations” in the Investors section of the Company’s website at www.avrobio.com. An archived webcast recording of the event will be available on the website for approximately 30 days.

About AVROBIO, Inc.

AVROBIO, Inc., is a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare diseases with a single dose. AVROBIO’s lentiviral-based gene therapies employ hematopoietic stem cells that are collected from the patient and then modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. AVROBIO is focused on the development of its gene therapy, AVR-RD-01, in Fabry disease, as well as additional investigational gene therapy programs including in Gaucher disease, cystinosis and Pompe disease. The Company’s plato™ platform incorporates a vector system and an automated, closed, cell manufacturing solution designed to enable worldwide commercialization. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON. For additional information, visit www.avrobio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190305005349/en/

CONTACT: Investors:

Christopher F. Brinzey

Westwicke Partners

339-970-2843

chris.brinzey@westwicke.comMedia:

Kathryn Morris

The Yates Network

914-204-6412

kathryn@theyatesnetwork.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS PHARMACEUTICAL

SOURCE: AVROBIO, Inc.

Copyright Business Wire 2019.

PUB: 03/05/2019 07:00 AM/DISC: 03/05/2019 07:01 AM

http://www.businesswire.com/news/home/20190305005349/en